Sandbox/AL: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
No edit summary
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Rosuvastatin}}
{{CMG}}; {{AE}}


'''''For patient information about Rosuvastatin, click [[Rosuvastatin (patient information)|here]].'''''
{{Rivaroxaban}}


{{SB}} CRESTOR<sup>®</sup>
{{CMG}}; {{AE}} {{AZ}}
 
'''''For patient information, click <u>[[Rivaroxaban (patient information)|here]]'''''</u>.
{{SB}} XARELTO<sup>®</sup>


==Overview==
==Overview==
'''Rivaroxaban''' (BAY 59-7939) is an [[route of administration|oral]] [[anticoagulant]]  invented and manufactured by [[Bayer]]; in a number of countries it is marketed as '''Xarelto'''.<ref name="Xarelto SPC">{{cite web |url=http://www.xarelto.com/scripts/pages/en/information-on-xarelto/summary_of_product_characteristics/index.php |title=Xarelto: Summary of Product Characteristics |publisher=Bayer Schering Pharma AG |year=2008 |accessdate=2009-02-11}}</ref> In the United States, it is marketed by [[Janssen Pharmaceutica]].<ref name="US Approval">{{cite press release |title=FDA Approves XARELTO® (rivaroxaban tablets) to Help Prevent Deep Vein Thrombosis in Patients Undergoing Knee or Hip Replacement Surgery |publisher=[[Janssen Pharmaceutica]] |date=2011-07-01 |url=http://m.prnewswire.com/news-releases/fda-approves-xarelto-rivaroxaban-tablets-to-help-prevent-deep-vein-thrombosis-in-patients-undergoing-knee-or-hip-replacement-surgery-124872829.html |accessdate=2011-07-01}}</ref> It is an orally active [[direct factor Xa inhibitor]]. Rivaroxaban is well absorbed from the gut and maximum inhibition of factor Xa occurs four hours after a dose. The effects lasts 8 to 12 hours, but factor Xa activity does not return to normal within 24 hours so once-daily dosing is possible.


'''Rosuvastatin''' is a member of the [[medication|drug]] class of [[statin]]s, used to treat [[hypercholesterolemia]] and related conditions, and to prevent [[cardiovascular disease]]. It is currently being marketed by the [[pharmaceutical company]] [[AstraZeneca]] as '''Crestor'''.
==Category==
==Category==
 
Direct [[Xa factor]] inhibitor.
Statins,Diols,Carboxylic acids,Sulfonamides,Pyrimidines,Organofluorides,Cardiovasular drugs.


==FDA Package Insert==
==FDA Package Insert==
''' [[Rosuvastatin indications and usage|Indications and Usage]]'''
=== XARELTO®===
'''| [[Rosuvastatin dosage and administration|Dosage and Administration]]'''
'''| [[Rivaroxaban indications and usage|Indications and Usage]]'''
'''| [[Rosuvastatin dosage forms and strengths|Dosage Forms and Strengths]]'''
'''| [[Rivaroxaban dosage and administration|Dosage and Administration]]'''
'''| [[Rosuvastatin contraindications|Contraindications]]'''
'''| [[Rivaroxaban dosage forms and strengths|Dosage Forms and Strengths]]'''
'''| [[Rosuvastatin warnings and precautions|Warnings and Precautions]]'''
'''| [[Rivaroxaban contraindications|Contraindications]]'''
'''| [[Rosuvastatin adverse reactions|Adverse Reactions]]'''
'''| [[Rivaroxaban warnings and precautions|Warnings and Precautions]]'''
'''| [[Rosuvastatin drug interactions|Drug Interactions]]'''
'''| [[Rivaroxaban adverse reactions|Adverse Reactions]]'''
'''| [[Rosuvastatin use in specific populations|Use in Specific Populations]]'''
'''| [[Rivaroxaban drug interactions|Drug Interactions]]'''
'''| [[Rosuvastatin overdosage|Overdosage]]'''
'''| [[Rivaroxaban use in specific populations|Use in Specific Populations]]'''
'''| [[Rosuvastatin description|Description]]'''
'''| [[Rivaroxaban overdosage|Overdosage]]'''
'''| [[Rosuvastatin clinical pharmacology|Clinical Pharmacology]]'''
'''| [[Rivaroxaban description|Description]]'''
'''| [[Rosuvastatin nonclinical toxicology|Nonclinical Toxicology]]'''
'''| [[Rivaroxaban clinical pharmacology|Clinical Pharmacology]]'''
'''| [[Rosuvastatin clinical studies|Clinical Studies]]'''
'''| [[Rivaroxaban nonclinical toxicology|Nonclinical Toxicology]]'''
'''| [[Rosuvastatin how supplied storage and handling|How Supplied/Storage and Handling]]'''
'''| [[Rivaroxaban clinical studies|Clinical Studies]]'''
'''| [[Rosuvastatin patient counseling information|Patient Counseling Information]]'''
'''| [[Rivaroxaban how supplied storage and handling|How Supplied/Storage and Handling]]'''
'''| [[Rosuvastatin labels and packages|Labels and Packages]]'''
'''| [[Rivaroxaban patient counseling information|Patient Counseling Information]]'''
'''| [[Rivaroxaban labels and packages|Labels and Packages]]'''


[[image:riva1.png|800px]]
==Mechanism of Action==
==Mechanism of Action==
XARELTO is a selective inhibitor of FXa. It does not require a cofactor (such as Anti-thrombin III) for activity. Rivaroxaban inhibits free FXa and prothrombinase activity. Rivaroxaban has no direct effect on platelet aggregation, but indirectly inhibits platelet aggregation induced by thrombin. By inhibiting FXa, rivaroxaban decreases thrombin generation.


CRESTOR is a selective and competitive inhibitor of [[HMG-CoA]] reductase, the rate-limiting enzyme that converts 3‑hydroxy‑3‑methylglutaryl coenzyme A to mevalonate, a precursor of [[cholesterol]]. In vivo studies in animals, and in vitro studies in cultured animal and human cells have shown rosuvastatin to have a high uptake into, and selectivity for, action in the liver, the target organ for [[cholesterol]] lowering. In in vivo and in vitro studies, rosuvastatin produces its lipid-modifying effects in two ways. First, it increases the number of hepatic LDL receptors on the cell-surface to enhance uptake and catabolism of LDL. Second, rosuvastatin inhibits hepatic synthesis of VLDL, which reduces the total number of VLDL and LDL particles.
==References==
==Interaction with Alcohol==


CRESTOR should be used with caution in patients who consume substantial quantities of alcohol and/or have a history of chronic liver disease.Chronic alcohol liver disease is known to increase rosuvastatin exposure.
==References==
{{Reflist|2}}
{{Reflist|2}}


{{Statins}}
[[Category:Statins]]
[[Category:AstraZeneca]]
[[Category:Carboxylic acids]]
[[Category:Sulfonamides]]
[[Category:Pyrimidines]]
[[Category:Organofluorides]]
[[Category:Cardiovasular drugs]]
[[Category:Drugs]]
[[Category:Drugs]]

Revision as of 14:24, 2 July 2014


Rivaroxaban
XARELTO® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
Clinical Studies
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
Clinical Trials on Rivaroxaban
ClinicalTrials.gov

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]

For patient information, click here. Synonyms / Brand Names: XARELTO®

Overview

Rivaroxaban (BAY 59-7939) is an oral anticoagulant invented and manufactured by Bayer; in a number of countries it is marketed as Xarelto.[1] In the United States, it is marketed by Janssen Pharmaceutica.[2] It is an orally active direct factor Xa inhibitor. Rivaroxaban is well absorbed from the gut and maximum inhibition of factor Xa occurs four hours after a dose. The effects lasts 8 to 12 hours, but factor Xa activity does not return to normal within 24 hours so once-daily dosing is possible.

Category

Direct Xa factor inhibitor.

FDA Package Insert

XARELTO®

| Indications and Usage | Dosage and Administration | Dosage Forms and Strengths | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Use in Specific Populations | Overdosage | Description | Clinical Pharmacology | Nonclinical Toxicology | Clinical Studies | How Supplied/Storage and Handling | Patient Counseling Information | Labels and Packages

Mechanism of Action

XARELTO is a selective inhibitor of FXa. It does not require a cofactor (such as Anti-thrombin III) for activity. Rivaroxaban inhibits free FXa and prothrombinase activity. Rivaroxaban has no direct effect on platelet aggregation, but indirectly inhibits platelet aggregation induced by thrombin. By inhibiting FXa, rivaroxaban decreases thrombin generation.

References

  1. ↑ "Xarelto: Summary of Product Characteristics". Bayer Schering Pharma AG. 2008. Retrieved 2009-02-11.
  2. ↑ "FDA Approves XARELTO® (rivaroxaban tablets) to Help Prevent Deep Vein Thrombosis in Patients Undergoing Knee or Hip Replacement Surgery" (Press release). Janssen Pharmaceutica. 2011-07-01. Retrieved 2011-07-01.
Retrieved from "https://www.wikidoc.org/index.php?title=Sandbox/AL&oldid=985349"